Palisade Bio has appointed Robert Baltera and Jordan Zwick to its Board of Directors, strengthening leadership with extensive biotech and capital markets experience. This move supports the company's progress with PALI-2108, an oral PDE4 inhibitor prodrug targeting inflammatory bowel diseases, which is advancing toward Phase 2 clinical trials. Both new board members bring expertise in biotech development, strategic transactions, and corporate governance, positioning Palisade for growth and value creation. The company aims to address significant unmet medical needs with its innovative therapies.
The Rosen Law Firm is investigating potential securities claims against Putnam Investment Management, LLC, alleging that the company may have provided misleading business information to investors. Investors who purchased Putnam stock-based mutual fun...
Several stocks experienced significant declines today driven by company-specific events. SANUWAVE Health's shares dropped 39.21% despite strong revenue guidance, Twin Vee Powercats fell 30.95% amid a legal investigation, and Gorilla Technology declin...
The phase III ENDURANCE trial showed that two years of lenalidomide maintenance therapy offers the same long-term survival benefit as indefinite treatment for patients with standard-risk multiple myeloma who are not transplant candidates. After nearl...
The stock market saw significant gains driven by corporate announcements and high trading volumes, particularly in battery technology, electric vehicles, and green energy sectors. Electrovaya surged 49.05% after announcing a commercial deal with Amaz...
An Akamai Technologies executive sold 3,100 shares as the company shifts focus from its declining content delivery network business to high-growth cloud infrastructure and cybersecurity services. This strategic pivot is supported by a $1.8 billion, s...
